A Randomized, Phase II Study Of Cx-01 Combined With Standard Induction Therapy For Newly Diagnosed Acute Myeloid Leukemia
Posted Date: May 15, 2019
- Investigator: Zartash Gul
- Type of Study: Drug
The purpose of the study is to find out whether or not the addition of the study drug, CX-01, to standard of care treatment for Acute Myeloid Leukemia (AML) increases the rate of remission. Remission means there is a decrease in, or disappearance of, signs or symptoms of cancer. In complete remissi
Criteria:
To Be Eligible To Participate In This Study, Patients Must Have Acute Myeloid Leukemia (Aml).
Keywords:
Acute Myeloid Leukem, Cancer, Cntx-Cx-01-2015-Aml-, Leukemia, Phase 2
For More Information:
Uc Cancer Center
(513) 584-7698
kastla@ucmail.uc.edu